The growing demand for biologic therapies is expected to fuel the market growth, owing to its ability to attack cancer cells effectively. For instance, REVLIMID and POMALYST reported a year-over-year (YoY) growth of 16.5% and 44.7%, respectively, in 2015, owing to the increased adoption of biologic therapies. The market has been witnessing a paradigm shift toward the adoption of novel proteasome inhibitors, owing to the increasing treatment failures with conventional chemotherapy drugs.

PART 01: Executive summary

PART 02: Scope of the report

Market overview

Top-vendor offerings

PART 03: Market research methodology

Research methodology

Economic indicators

PART 04: Introduction

Key market highlights

PART 05: Disease overview

Understanding the disease

PART 06: Pipeline analysis

PART 07: Market landscape

Global multiple myeloma drugs market

Five forces analysis

PART 08: Market segmentation by therapy

Targeted therapy

Biologic therapy

Chemotherapy

Others

PART 09: Geographical segmentation

Multiple myeloma drugs market in Americas

Multiple myeloma drugs market in EMEA

Multiple myeloma drugs market in APAC

PART 10: Market drivers

Growing demand for biologic therapies

Paradigm shift toward the adoption of novel proteasome

inhibitors

Presence of large patient pool

PART 11: Impact of drivers

PART 12: Market challenges

Growing popularity of complementary and alternative

medicines (CAM)

High costs affecting the adoption rates of multiple

myeloma drugs

Adverse effects of drugs

PART 13: Impact of drivers and challenges

PART 14: Market trends

Emergence of nanomedicine platform

Advent of microRNA therapeutics

Increasing inorganic growth strategies

PART 15: Vendor landscape

Competitive scenario

PART 16: Key vendor analysis

Amgen

Celgene

Johnson & Johnson

Novartis

Takeda Pharmaceuticals

Other prominent vendors

PART 17: Appendix

List of abbreviations

PART 18: Explore Technavio